There have been many studies proving that depression interferes with medication adherence, but it isn't enough to just treat depression to get better outcomes, providers have to hand hold patients and help them improve their motivation to start taking medications again, explained Paul Ciechanowski, MD, MPH, associate professor at the University of Washington.
There have been many studies proving that depression interferes with medication adherence, but it isn't enough to just treat depression to get better outcomes, providers have to hand hold patients and help them improve their motivation to start taking medications again, explained Paul Ciechanowski, MD, MPH, associate professor at the University of Washington.
Transcript (slightly modified for readability)
How often does depression serve as a barrier to good medication adherence?
As far as depression being a barrier, when a person is depressed, first of all they feel sluggish, low energy, low motivation, they have problems concentrating, they get easily overwhelmed, and frankly a lot of times they're just saying, "What's the use?" Their motivation just goes out the window. And sometimes depressed people have suicidal thoughts, or they're just passively suicidal, and they're just thinking "Why do I even need to take these medications? I don't even feel like living."
So just thinking about that at a clinical level, that's a huge barrier to people taking any kind of treatment. What we know from our studies, when we look at depressed people at Group Healt Cooperative [in Seattle, Washington], for example, who are in the top tertile of depression compared to the bottom tertile, the difference was double: 14% had lapses in their medications if we looked at pharmacy data, compared to 7%. In another study that we did, we looked at lipid-lowering agents and among people who were depressed they had 50% more nonadherence. Among people taking ACE [angiotensin-converting-enzyme] inhibitors they were 33% more likely to be nonadherence if they were depressed.
So we've seen this over and over and any clinician will say "Yeah, no kidding, depression gets in the way." At every level it affects patients, and that's why we need to really aggressively treat depression, but what we've discovered in our trials is it's not just enough to treat depression to get better outcomes, you also have to hand hold and help patients be convinced and improve their motivation once the depression starts to go away to get them to start taking their medications again.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More